WV SB297

Requires coverage of intravenous immunoglobulin (IVIG) therapy for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), pediatric acute onset neuropsychiatric syndrome (PANS), and other autoimmune encephalopathies

Applies to West Virginia Public Employees Insurance (PEIA), Medicaid, and private health insurance plans including accident and sickness insurance, group insurance, hospital/medical service corporations, health care corporations, and HMOs

Coverage is conditional on the physician obtaining prior authorization and demonstrating that all other treatments have been exhausted before IVIG therapy will be approved

Takes effect for plans issued or renewed after January 1, 2026, for most insurance types, and after July 1, 2026, for PEIA plans

Adds seven new sections to the West Virginia Code across multiple chapters governing different types of health coverage